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EFFECTS

ABSTRACT
The truncated glucagon-like peptide-1 (GLP-1(7.36,amide or GLP-1) stimulates insulin secretion, enhances glucose elimination and is of potential interest in diabetes treatment. We studied the hypoglycemic action of GLP-l in normal mice when given alone or together with the fiuctose analogue, 2,5-anhydro-D-mannitol (2,5-AM), which inhibits glycogenolysis and gluconeogenesis. GLP-1 (32 nmovkg iv) lowered plasma glucose levels after 25 min to 4.6kO.2 mmovl compared with 7.3f0.4 mmoVl in controls (P<O.OOl). Also 2,5-AM (0.5 VmoVkg iv) reduced plasma glucose levels, to 5.6kO.3 mmoyl (P<O.Ol). When given together, the glucose lowering action of GLP-1 and 2,5-AM was additive, since the 25 min glucose level was 2.8kO.2 mmoyl. At 5 min after injection, GLP-1 had increased plasma insulin levels to 693+68 pmoVl compared with 342f42 pmovl in controls (P<O.Ol). 2,5-AM abolished this increase. Furthermore, GLP-I (32 nmokg) did not affect the glycogen content, neither in the liver nor in the gastrocnemic muscle in samples taken at 30 min after injection. Moreover, in isolated islets incubated at 3.3 and 8.3 mmol/l glucose, 2,5-AM at 75 mmoyl inhibited glucose-stimulated insulin secretion (Pc0.05) showing that 2,s-AM inhibits insulin secretion both in vivo and in vitro. We conclude that GLP-1 may reduce plasma glucose levels also to levels below the basal levels under normal conditions, and that an insulin-and liver-independent action of the peptide contributes to its hypoglycemic action in normal animals.
INTRODUCTION A H R~N ET AL.
During recent years, the truncated form of glucagon-like peptide-1 , GLP-1(7-s6pnide, or, as it is called here, GLP-I, has been postulated to be a potential new treatment modality for diabetes (1). This suggestion is based on studies showing that GLP-1 stimulates insulin secretion and lowers blood glucose concentrations both under normal conditions and in diabetes (1-6). Furthermore, the insulinotropic action of GLP-1 is glucose-dependent (7,s) which makes hypoglycemia unlikely to evolve following administration of the peptide. This conclusion is supported by our previous study which demonstrated that in normal mice, an intravenous injection of a high dose of GLP-1 stimulates a short-lived and transient insulin secretion with no hypoglycemia during the first 10 min after injection (3).
However, we have previously also demonstrated that GLP-I enhances the glucose elimination rate during an intravenous glucose tolerance test both in normal and in insulin-deficient alloxan-diabetic mice (9), and, similarly, that the peptide increases the insulin sensitivity during a hyperglycemic clamp in patients with insulin-deficient type 1 diabetes (1). This suggests that GLP-I also might lower the blood glucose concentrations by a peripheral, insulin-independent, action. This could indicate that GLP-1 would reduce the glycemia also to levels below those seen basally and therefore indeed induce hypoglycemia but that this would evolve at a later time point than that seen for its insulinotropic action. In this study, we have therefore examined the time course of plasma glucose levels after an intravenous injection of GLP-1 in normoglycemic mice. We have also studied whether the fructose analogue, 2,5,anhydro-D-mannitol (2,5-AM), affects the action of GLP-1 GLP-1, 2,5-AM AND INSULIN SECRETION 585 on plasma glucose levels, since 2,5-AIvl has previously been demonstrated to induce hypoglycemia in mice through inhibiting gluconeogenesis and glycogenolysis and thereby hepatic glucose delivery (10). Thus, administration of 2,5-AM would, first, preclude any hepatic actions of GLP-1 and, second, the simultaneous use of 2,5-AM and GLP-1 would allow conclusions on the issue whether GLP-1 could induce severe hypoglycemia. To study the possibility that a glycogenic action of GLP-1 contributes to its hypoglycemic effect, liver and muscle glycogen content were also examined. Furthermore, during the course of this study, we demonstrated that insulin secretion in mice was inhibited by 2,5-AM. Therefore, we also studied whether such an action is mediated by a direct islet action of the substance by examining insulin secretion from isolated mouse islets.
MATERIALS AND METHODS
Animals.
Adult female NMRl mice (Bomholtgird Breeding and Research Centre Ltd, Ry, Denmark), weighing 22-25 g, were used. The animals had been kept on a standard pellet diet and tap water ad libitum before the experiments. The study was approved by the Ethic Committee of the Lund University.
In vivo exDeriments.
The mice were anesthetized with thipenthal 1.8 mglanimal injected ip. 
In vitro exDeriments.
Islets were isolated by the collagenase digestion technique (1 1,12). In brief, pancreas was retrogradely filled with 3 ml of Hank's Balanced Salt Solution (Sigma Chemical Co., St. Louis, U.S.A.), supplemented with 0.3 mg/ml of Collagenase P (Boehringer Mannheim Gmbh, Germany). The pancreas was subsequently removed and incubated for 20 min at 37°C. After rinsing, the islets were handpicked under a stereomicroscope and incubated overnight in RPMI 1640 medium.
The islets were then washed three times and preincubated for 30 min at 37°C in a modified Krebs-Ringer bicarbonate medium, consisting of (in mmol/l): 114 NaCl, 4.4 KCl, 1.28 CaC12, 1.5 KHPO4, 0.8 MgSO4, and 24 NaHC03, 10 Hepes and 3.3 glucose in 95% humified air/5% C02 athmosphere. The islets were then transferred to new chambers, and single islets were incubated individually in 0.1 ml of the Krebs-Ringer bicarbonate medium for 60 min at 37OC in an athmosphere of 95% air/5% COZ in the presence of 3.3 or 8.3 mmovl glucose and/or 1.5, 7.5, 15 or 75 mmol/l2,5-AM according to the respective protocols. After the 60 min incubation, aliquots of the medium (2x25 pl) were removed for insulin immunoassay.
Analyses.
The concentration of insulin in plasma and medium was determined by radioimmunoassay using guinea pig anti porcine insulin (Linco Research, St Louis, Mo,
USA),
I-labelled rat insulin (NOVO Nordic, Bagsvaerd, Denmark) and, as standard, rat insulin (Linco). The antigen-antibody complex was dissociated by the double antibody technique (13). Plasma glucose levels were determined with the glucose oxidase technique. Tissue glycogen content was performed in homogenized tissue as analysis of glucose after glycogen breakdown (14) .
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Statistics.
Values are expressed as mean f SEM. The statistical comparisons were performed using two-way analysis of variance with the Neumann-Keul post hoc test.
A probability level of random difference of P<0.05 was considered significant.
RESULTS
Studies in viva
The intravenous injection of GLP-1 at 32 nmoykg was followed by a reduction in plasma glucose levels that was most marked at 25 min after the injection (Fig. 1) . There were 12 animals in each group.
Similarly, 2,5-AM at 0.5 pmoykg reduced plasma glucose levels (Fig.1) . When combined, GLP-1 and 2,5-AM induced additive hypoglycemic responses. Plasma insulin levels were increased by GLP-1 at 5 min after injection (Table I) 
Studies in vitro.
When isolated mouse islets were incubated for 60 min, 2,5-AM at 75 mmovl inhibited glucose-(8.3 mmoV1)-stimulated insulin secretion. Thus, at 8.3 mmoVl glucose, the medium insulin secretion was 7 568+567 pmoVl (n=24 batch incubations performed at 3 occassions) and this figure was reduced to 5 288+861 pmoVl by 2,5-AM at 75 mmoVl (P<0.,05; n=24). In contrast, at lower doses, 2,5-Ah4 did not significantly affect glucose-stimulated insulin secretion.
DISCUSSION
In liver cells, the p-D-fructose analogue, 2,5-AM, is phosphorylated by fructokinase to 2,5-AM-1 -phosphate which is subsequently phosphorylated by phosphofructokinase to 2,5-AM-2,6-biphosphate (1 5 ) . This compound is not fkrther metabolized but is instead accumulated inside the cells in which it inhibits both gluconeogenesis and glycogenolysis (10, (15) (16) (17) evolves that reduces the cellular content of ATP (1 9). Previously, these actions of 2,S-AM have been shown to result in hypoglycemia when administered both in normal and diabetic mice and rats (10, 20) . We confirm in this study that 2,5-AM reduces plasma glucose levels in non-fasted normal mice.
In this study, we also demonstrate that 2,5-AM inhibits insulin secretion, both GLP-I has previously been shown to stimulate insulin secretion and to enhance the glucose elimination in nomal mice (3, 8, 9) . In this study, we show that GLP-1, besides increasing plasma insulin levels, also lowers the plasma glucose to levels below those seen normally in normal mice, an effect that is seen at 15 min after its On the other hand, a study in humans has shown that GLP-I increases the insulinindependent peripheral glucose uptake (24), which suggests a peripheral, but insulin-independent, site of action. Our present study in normal mice therefore supports this suggestion. The exact mechanism underlying the hypoglycemic action of GLP-1 still remains intriguing, however, although stimulation of peripheral glucose uptake, for example in muscles, is at present the most likely explanation. In this context, it is of interest that a recent study has demonstrated that GLP-1 binds to skeletal muscles (25).
In conclusion, this study has shown 1)that the fiuctose analogue, 2,5-anhydro-D-mannitol inhibits insulin secretion both in vivo and in vitro, 2)that GLP-I may reduce plasma glucose levels also to levels below the basal levels, and 3)that the glucose lowering action of GLP-1 seems to be mediated by an insulin-independent and probably also a liver-independent action.
